keyword
MENU ▼
Read by QxMD icon Read
search

cost-effectiveness and juvenile idiopathic arthritis

keyword
https://www.readbyqxmd.com/read/27641835/parents-information-needs-and-influential-factors-when-making-decisions-about-tnf-%C3%AE-inhibitors
#1
Ellen A Lipstein, Daniel J Lovell, Lee A Denson, Sandra C Kim, Charles Spencer, Maria T Britto
BACKGROUND: Parents struggle when making treatment decisions for children with arthritis or other chronic conditions. Understanding their decision-making process is an essential step towards improving the decision-making experience. The objective of this study was to describe parents' information needs and the influences on their decision making about treatment with TNF-α inhibitors. METHODS: Survey domains were developed based on qualitative data and cognitive interviewing...
September 15, 2016: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/27135404/the-clinical-effectiveness-and-cost-effectiveness-of-abatacept-adalimumab-etanercept-and-tocilizumab-for-treating-juvenile-idiopathic-arthritis-a-systematic-review-and-economic-evaluation
#2
Jonathan Shepherd, Keith Cooper, Petra Harris, Joanna Picot, Micah Rose
BACKGROUND: Juvenile idiopathic arthritis (JIA) is characterised by joint pain, swelling and a limitation of movement caused by inflammation. Subsequent joint damage can lead to disability and growth restriction. Treatment commonly includes disease-modifying antirheumatic drugs (DMARDs), such as methotrexate. Clinical practice now favours newer drugs termed biologic DMARDs where indicated. OBJECTIVE: To assess the clinical effectiveness and cost-effectiveness of four biologic DMARDs [etanercept (Enbrel(®), Pfizer), abatacept (Orencia(®), Bristol-Myers Squibb), adalimumab (Humira(®), AbbVie) and tocilizumab (RoActemra(®), Roche) - with or without methotrexate where indicated] for the treatment of JIA (systemic or oligoarticular JIA are excluded)...
April 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27059807/cost-effectiveness-analysis-of-first-line-treatment-with-biologic-agents-in-polyarticular-juvenile-idiopathic-arthritis
#3
Nadia J Luca, Heather F Burnett, Wendy J Ungar, Myla E Moretti, Timothy Beukelman, Brian M Feldman, Gwen Schwartz, Ahmed M Bayoumi
OBJECTIVE: The optimal timing of biologic agent treatment in polyarticular juvenile idiopathic arthritis (JIA) is unknown. This study evaluated the costs and outcomes of first-line treatment with etanercept (ETN), an anti-tumor necrosis factor (anti-TNF) agent, compared with step-wise therapy in JIA. METHODS: We compared 2 strategies: methotrexate (MTX) plus ETN as first-line therapy (ETN-first) and MTX monotherapy followed by ETN (ETN-second), using a cohort state-transition model of newly diagnosed JIA patients...
April 5, 2016: Arthritis Care & Research
https://www.readbyqxmd.com/read/26812448/sonologic-enthesitis-in-children-with-enthesitis-related-arthritis
#4
COMPARATIVE STUDY
Sajjan Shenoy, Amita Aggarwal
OBJECTIVES: Enthesitis is an important clinical manifestation and is a diagnostic criterion for juvenile idiopathic enthesitis-related arthritis (JIA-ERA). Ultrasound (US) is a highly sensitive method of detection of enthesitis in adult spondyloarthropathies. However, since the data on JIA and the preformance of US compared to clinical examination is limited, we aimed to compare the accuracy of US and clinical examination in JIA-ERA. METHODS: Patients with JIA-ERA (ILAR criteria) were enrolled in the study after consent...
January 2016: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/26806845/a-novel-reactive-epitope-based-antigen-targeted-by-serum-autoantibodies-in-oligoarticular-and-polyarticular-juvenile-idiopathic-arthritis-and-development-of-an-electrochemical-biosensor
#5
Galber R Araujo, Patricia T Fujimura, Emília R Vaz, Tamiris A Silva, Vinícius R Rodovalho, Ana Graci Britto-Madurro, João M Madurro, João E Fonseca, Carlos H M Silva, Paula S Santos, Ana F Mourão, Helena Canhão, Luiz R Goulart, João Gonçalves, Carlos Ueira-Vieira
Currently, there are no specific markers for juvenile idiopathic arthritis (JIA) diagnosis, which is based on clinical symptoms and some blood tests for diseases' exclusion. Aiming to select new epitope-based antigens (mimotopes) that could recognize circulating autoantibodies in most JIA forms, we screened a phage displayed random peptide library against IgG antibodies purified from serum of JIA patients. ELISA assay was carried out to confirm immunoreactivity of selected peptides against sera IgG antibodies from JIA patients, healthy children and patients with other autoimmune diseases...
May 2016: Immunobiology
https://www.readbyqxmd.com/read/26599495/managing-juvenile-idiopathic-arthritis-associated-uveitis
#6
REVIEW
Madeleine J Hawkins, Andrew D Dick, Richard J W Lee, Athimalaipet V Ramanan, Ester Carreño, Catherine M Guly, Adam H Ross
Bilateral chronic anterior uveitis is an extra-articular feature of juvenile idiopathic arthritis. Although figures vary, uveitis occurs in approximately 11%-13% of patients with this disease and is most commonly associated with the female gender, oligoarthritis, and presence of antinuclear antibodies. The disease has an insidious onset and is often asymptomatic. Managing patients with juvenile idiopathic arthritis-associated uveitis remains challenging as the disease may prove to be refractory to traditional treatment regimens...
March 2016: Survey of Ophthalmology
https://www.readbyqxmd.com/read/26533625/cost-effectiveness-analysis-of-canacinumab-in-the-treatment-of-patients-suffering-from-systemic-juvenile-idiopathic-arthritis-in-russian-federation
#7
R Yagudina, A Kulikov, A Pochuprina
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/26314390/prevalence-of-severe-fatigue-among-adolescents-with-pediatric-rheumatic-diseases
#8
Linde N Nijhof, Elise M van de Putte, Nico M Wulffraat, Sanne L Nijhof
OBJECTIVE: To determine the prevalence of severe fatigue and fatigue-related limitations among adolescents with juvenile idiopathic arthritis (JIA) and other pediatric rheumatic diseases (PRDs). In addition, we assessed the effect of disease activity and pain on the severity of fatigue. METHODS: This cross-sectional study included 175 patients (ages 10-18 years) who visited the pediatric rheumatology and immunology outpatient clinic at Wilhelmina Children's Hospital from April through July 2013...
January 2016: Arthritis Care & Research
https://www.readbyqxmd.com/read/26036945/immunogenicity-and-safety-of-the-human-papillomavirus-vaccine-in-patients-with-autoimmune-diseases-a-systematic-review
#9
REVIEW
Paolo Pellegrino, Sonia Radice, Emilio Clementi
Whereas safety and efficacy of HPV vaccines in healthy women have been shown in several randomised controlled clinical trials and in post marketing analyses, only few data exist in patients affected by autoimmune diseases. These issues are significant as autoimmune conditions are recognised as a risk factor for the persistence of HPV infection. Herein we review and systematise the existing literature to assess immunogenicity and safety of HPV vaccination in patients with autoimmune diseases, including systemic lupus erythematosus and juvenile idiopathic arthritis...
July 9, 2015: Vaccine
https://www.readbyqxmd.com/read/25874347/the-humanistic-and-economic-burden-of-juvenile-idiopathic-arthritis-in-the-era-of-biologic-medication
#10
REVIEW
Wendy Gidman, Rachel Meacock, Deborah Symmons
Juvenile idiopathic arthritis (JIA) is a poorly understood, heterogeneous, incurable, inflammatory syndrome. Long-term outcomes are uncertain, and this painful condition can result in lifelong disability. JIA is associated with considerable financial and humanistic burden for those affected and the healthcare system. Early diagnosis and effective treatment are indicated to optimise outcomes. Modern treatment aims to achieve remission and preserve joint function by using disease-modifying antirheumatic drugs (DMARDs) early...
May 2015: Current Rheumatology Reports
https://www.readbyqxmd.com/read/25803793/psychological-therapies-remotely-delivered-for-the-management-of-chronic-and-recurrent-pain-in-children-and-adolescents
#11
REVIEW
Emma Fisher, Emily Law, Tonya M Palermo, Christopher Eccleston
BACKGROUND: Chronic pain is common during childhood and adolescence and is associated with negative outcomes such as increased severity of pain, reduced function (e.g. missing school), and low mood (e.g. high levels of depression and anxiety). Psychological therapies, traditionally delivered face-to-face with a therapist, are efficacious at reducing pain intensity and disability. However, new and innovative technology is being used to deliver these psychological therapies remotely, meaning barriers to access to treatment such as distance and cost can be removed or reduced...
2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/25498778/parents-willingness-to-pay-for-biologic-treatments-in-juvenile-idiopathic-arthritis
#12
Heather F Burnett, Wendy J Ungar, Dean A Regier, Brian M Feldman, Fiona A Miller
BACKGROUND: Biologic therapies are considered the standard of care for children with the most severe forms of juvenile idiopathic arthritis (JIA). Inconsistent and inadequate drug coverage, however, prevents many children from receiving timely and equitable access to the best treatment. OBJECTIVE: The objective of this study was to evaluate parents' willingness to pay (WTP) for biologic and nonbiologic disease-modifying antirheumatic drugs (DMARDs) used to treat JIA...
December 2014: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/25369205/temporomandibular-joint-diagnostics-using-cbct
#13
REVIEW
T A Larheim, A-K Abrahamsson, M Kristensen, L Z Arvidsson
The present review will give an update on temporomandibular joint (TMJ) imaging using CBCT. It will focus on diagnostic accuracy and the value of CBCT compared with other imaging modalities for the evaluation of TMJs in different categories of patients; osteoarthritis (OA), juvenile OA, rheumatoid arthritis and related joint diseases, juvenile idiopathic arthritis and other intra-articular conditions. Finally, sections on other aspects of CBCT research related to the TMJ, clinical decision-making and concluding remarks are added...
2015: Dento Maxillo Facial Radiology
https://www.readbyqxmd.com/read/25244345/an-update-on-disease-modifying-antirheumatic-drugs
#14
REVIEW
Poorvashree Joshi, Suneela S Dhaneshwar
Disease modifying antirheumatic drugs (DMARDs) is a category of drugs which is used as medication in various arthritic conditions to arrest the progression of disease along with relief from pain. About 83% of population worldwide uses DMARDs. Withdrawal of COX-2 inhibitors because of cardiovascular side effects and short-term action associated with glucocorticoids provided a motivation for development of newer DMARDs. Currently non- biological DMARDs like methotrexate, sulfasalazine, hydroxychloroquine and azathioprine serve the purpose of relieving pain and inhibiting the progression of disease...
2014: Inflammation & Allergy Drug Targets
https://www.readbyqxmd.com/read/25187470/the-association-between-low-socioeconomic-status-with-high-physical-limitations-and-low-illness-self-perception-in-patients-with-juvenile-idiopathic-arthritis-results-from-the-childhood-arthritis-prospective-study
#15
COMPARATIVE STUDY
Suzanne M M Verstappen, Joanna Cobb, Helen E Foster, Bo Fu, Eileen Baildam, Lucy R Wedderburn, Joyce E Davidson, John Ioannou, Alice Chieng, Kimme L Hyrich, Wendy Thomson
OBJECTIVE: To examine the association between socioeconomic status (SES) and delay to a pediatric rheumatology clinic, disease severity, and illness perception in patients with juvenile idiopathic arthritis in England. METHODS: Using the Index of Multiple Deprivation, 923 consecutive children from the Childhood Arthritis Prospective Study were assigned to SES groups: high-SES (19.1%), middle-SES (44.5%), or low-SES (36.4%). At baseline, disease activity was assessed, and the Childhood Health Assessment Questionnaire (C-HAQ), the Illness Perception Questionnaire, and the Child Health Questionnaire, version Parent Form 50, were completed...
March 2015: Arthritis Care & Research
https://www.readbyqxmd.com/read/25034360/etanercept-a-review-of-its-use-in-autoimmune-inflammatory-diseases
#16
REVIEW
Lesley J Scott
With its approval more than 15 years ago, subcutaneous etanercept (Enbrel(®)) was the first biological disease-modifying antirheumatic drug (bDMARD) and the first tumour necrosis factor inhibitor to be approved for use in rheumatic diseases. Etanercept remains an important cost-effective treatment option in adult patients with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis, and in paediatric patients with juvenile idiopathic arthritis or plaque psoriasis. In all of these populations, etanercept (with or without methotrexate) effectively reduced signs and symptoms, disease activity and disability, and improved health-related quality of life, with these benefits sustained during long-term treatment...
August 2014: Drugs
https://www.readbyqxmd.com/read/24774505/adalimumab-in-the-treatment-of-immune-mediated-diseases
#17
REVIEW
G Lapadula, A Marchesoni, A Armuzzi, C Blandizzi, R Caporali, S Chimenti, R Cimaz, L Cimino, P Gionchetti, G Girolomoni, P Lionetti, A Marcellusi, F S Mennini, C Salvarani
Tumour necrosis factor (TNF) plays an important role in the pathogenesis of immune-mediated inflammatory diseases (IMIDs). TNF inhibition results in down-regulation of abnormal and progressive inflammatory processes, resulting in rapid and sustained clinical remission, improved quality of life and prevention of target organ damage. Adalimumab is the first fully human monoclonal antibody directed against TNF. In this article, we review the role and cost effectiveness of adalimumab in the treatment of IMIDs in adults and children...
January 2014: International Journal of Immunopathology and Pharmacology
https://www.readbyqxmd.com/read/24600203/update-on-the-use-of-systemic-biologic-agents-in-the-treatment-of-noninfectious-uveitis
#18
REVIEW
Sirichai Pasadhika, James T Rosenbaum
Uveitis is one of the leading causes of blindness worldwide. Noninfectious uveitis may be associated with other systemic conditions, such as human leukocyte antigen B27-related spondyloarthropathies, inflammatory bowel disease, juvenile idiopathic arthritis, Behçet's disease, and sarcoidosis. Conventional therapy with corticosteroids and immunosuppressive agents (such as methotrexate, azathioprine, mycophenolate mofetil, and cyclosporine) may not be sufficient to control ocular inflammation or prevent non-ophthalmic complications in refractory patients...
2014: Biologics: Targets & Therapy
https://www.readbyqxmd.com/read/24591462/us-trends-in-rates-of-arthroplasty-for-inflammatory-arthritis-including-rheumatoid-arthritis-juvenile-idiopathic-arthritis-and-spondyloarthritis
#19
COMPARATIVE STUDY
Christina Mertelsmann-Voss, Stephen Lyman, Ting Jung Pan, Susan M Goodman, Mark P Figgie, Lisa A Mandl
OBJECTIVE: Although rates of arthroplasty have increased dramatically, rates among patients with rheumatoid arthritis (RA) are reported to be decreasing. It is not known if this is also the case among patients with other inflammatory arthritides. This study was undertaken to evaluate rates of arthroplasty due to RA, juvenile idiopathic arthritis (JIA), spondyloarthritis (SpA), and a composite group of patients with inflammatory arthritides (IA), compared to arthroplasty rates among patients without inflammatory or autoimmune conditions...
June 2014: Arthritis & Rheumatology
https://www.readbyqxmd.com/read/24405833/a-randomised-controlled-trial-of-the-clinical-effectiveness-safety-and-cost-effectiveness-of-adalimumab-in-combination-with-methotrexate-for-the-treatment-of-juvenile-idiopathic-arthritis-associated-uveitis-sycamore-trial
#20
RANDOMIZED CONTROLLED TRIAL
Athimalaipet V Ramanan, Andrew D Dick, Diana Benton, Sandrine Compeyrot-Lacassagne, Dalia Dawoud, Ben Hardwick, Helen Hickey, Dyfrig Hughes, Ashley Jones, Patricia Woo, Clive Edelsten, Michael W Beresford
BACKGROUND: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Children with JIA are at risk of inflammation of the uvea in the eye (uveitis). Overall, 20% to 25% of paediatric uveitis is associated with JIA. Major risk factors for development of uveitis in JIA are oligoarticular pattern of arthritis, an age at onset of arthritis of less than seven years of age, and antinuclear antibody positivity. In the initial stages of mild to moderate inflammation the uveitis is asymptomatic...
January 9, 2014: Trials
keyword
keyword
110958
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"